Durect News

Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)

TipRanksMay 22 09:10 ET

Durect Analyst Ratings

BenzingaMay 22 06:27 ET

Durect Analyst Ratings

BenzingaMay 15 10:54 ET

Durect (DRRX) Gets a Buy From Oppenheimer

TipRanksMay 14 08:03 ET

Durect Analyst Ratings

BenzingaApr 1 09:21 ET

Durect Analyst Ratings

BenzingaMar 28 08:11 ET

Analysts Offer Insights on Healthcare Companies: NexGel Inc (NXGL), Taysha Gene Therapies (TSHA) and Durect (DRRX)

TipRanksNov 15, 2023 08:02 ET

Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Spero Therapeutics (SPRO) and EFFECTOR Therapeutics (EFTR)

TipRanksNov 14, 2023 06:40 ET

Durect Analyst Ratings

BenzingaNov 9, 2023 04:47 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Durect (DRRX) and Praxis Precision Medicines (PRAX)

TipRanksNov 8, 2023 16:40 ET

HC Wainwright Downgrades DURECT to Neutral, Removes Price Target

Seeking AlphaNov 8, 2023 14:30 ET

Durect Analyst Ratings

BenzingaNov 8, 2023 08:21 ET

Durect (DRRX) Was Downgraded to a Hold Rating at H.C. Wainwright

TipRanksNov 8, 2023 06:44 ET

H.C. Wainwright Reaffirms Their Buy Rating on Durect (DRRX)

TipRanksSep 7, 2023 11:15 ET

Analysts Offer Insights on Healthcare Companies: Durect (DRRX) and Cytokinetics (CYTK)

TipRanksAug 11, 2023 08:01 ET

Cantor Fitzgerald Adjusts Price Target on Durect to $41 From $44, Keeps Overweight Rating

MT NewswiresAug 10, 2023 10:38 ET

HC Wainwright & Co. Maintains Buy on Durect, Lowers Price Target to $27

BenzingaAug 10, 2023 07:36 ET

Durect Analyst Ratings

BenzingaAug 10, 2023 07:35 ET

Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Pfizer (PFE) and BioVie (BIVI)

TipRanksMay 17, 2023 12:30 ET

Analyst Ratings for Durect

BenzingaMay 17, 2023 12:01 ET